ESPR 241220 2.00P (ESPR241220P2000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ESPR241220P2000

Watchlist

0.05
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.15High0.05Low

Intraday

5D
Daily

News

12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaDec 13 16:06 ET
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsDec 13 13:31 ET · Ratings
Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham
Dow JonesDec 13 12:44 ET · Ratings
Express News | Esperion Enters Privately Negotiated Exchange And Subscription Agreements With Certain Holders Of 4.00% Convertible Senior Subordinated Notes Due 2025
BenzingaDec 13 06:01 ET
Esperion Announces $210M Convertible Debt Financing
Dow JonesDec 13 06:01 ET
Press Release: Esperion Announces $210 Million Convertible Debt Financing
Dow JonesDec 13 06:00 ET

Comments

10xStockPicks

4 hours ago

Esperion Is An Acquisition Target. Very Favorable New Debt Terms For Investors Offers Excellent Buying Opportunity 10x Upside Potential. Profitable in 2025.

$Esperion Therapeutics (ESPR.US) is the only pharmaceutical company with statin alternative medications Nexletol & Nexlizet for primary prevention with compounding monthly script growth in a massive market space, 21M Americans need statin alternative medications, either due to statin intolerance or need additional LDLC lowering. ESPR now...

AB84

Dec 13 09:10

Hold

$Esperion Therapeutics (ESPR.US)$ 10 bagger one of these days

UnluckyDog

Dec 13 08:13

$Esperion Therapeutics (ESPR.US)$
gone for good ? 😢

DazzlerAus

Dec 12 08:35

$Esperion Therapeutics (ESPR.US)$

Jaguar8

Dec 12 07:07

NEWS

$Esperion Therapeutics (ESPR.US)$
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...